Active Not Recruiting PHASE3 INTERVENTIONAL 3-arm NCT06934226

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ASCEND)

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Sponsor: Janssen Research & Development, LLC

Conditions Plaque Psoriasis

Interventions JNJ-77242113 Matching Placebo to JNJ-77242113 Matching Placebo to Ustekinumab Ustekinumab

Updated 14 times since 2025 Last updated: Mar 12, 2026 Started: Apr 15, 2025 Primary completion: Mar 30, 2026 Completion: Aug 20, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06934226, this PHASE3 trial focuses on Plaque Psoriasis and remains ongoing. Sponsored by Janssen Research & Development, LLC, it has been updated 14 times since 2025, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

14 versions recorded

Mar 2026 — Present [monthly]

Active Not Recruiting PHASE3
Mar 2026 — Present [monthly]

Active Not Recruiting PHASE3
Feb 2026 — Mar 2026 [monthly]

Active Not Recruiting PHASE3
Feb 2026 — Present [monthly]

Active Not Recruiting PHASE3
Jan 2026 — Present [monthly]

Active Not Recruiting PHASE3

▶ Show 9 earlier versions

Jan 2026 — Feb 2026 [monthly]

Active Not Recruiting PHASE3
Dec 2025 — Jan 2026 [monthly]

Active Not Recruiting PHASE3
Nov 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE3
Oct 2025 — Nov 2025 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE3
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE3
Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE3
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
May 2025 — Jun 2025 [monthly]

Not Yet Recruiting PHASE3

First recorded

Apr 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Research & Development, LLC

Data source: Janssen Research & Development, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Aarhus, Denmark , Ajax, Canada , Alicante, Spain , Alpharetta, United States , Arlington, United States , Augsburg, Germany , Bad Bentheim, Germany , Barakaldo, Spain , Barcelona, Spain and 129 more locations